Kailera Therapeutics opens at $26 per share after IPO
Kailera Therapeutics priced its initial public offering at $16 per share. The company is a potential competitor to Eli Lilly and Novo Nordisk in the obesity treatment market.
The GLP-1 drug market could reach $190 billion by 2035, doubling 2025 levels. Kailera is building a weight-loss drug pipeline with four candidates in various trial stages.
Kailera’s lead-drug candidate, Ribupatide, is in phase 3 trials and has the potential to be a category-leading treatment for people living with obesity. The company offers a fresh opportunity in a sector with limited new biotech offerings.
Investing in Kailera carries risks, as the company has no commercial products and the biotech sector is notoriously volatile.